Page 282 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
UF], RE 2857/2-1 and KFO 337 [to MR]), the German Cancer Aid (Deutsche Krebshilfe, grant no. 111537 [to MR]) and the “Cancer Prevention - Graduate School” by German Cancer Aid, grant no. 70114736 and coordinated by the German Cancer Research Center (DKHZ), grant no. 70114766 (to UF), and the Saint Baldrick’s Robert
References
1. Perez-Riverol Y, Bai J, Bandla C, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50(D1):D543-D552.
2. Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015;47(9):1020-1029.
3. Yang M, Vesterlund M, Siavelis I, et al. Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia. Nat Commun. 2019;10(1):1519.
4. Huang Y, Mouttet B, Warnatz HJ, et al. The Leukemogenic TCF3-HLF complex rewires enhancers driving cellular identity and self-renewal conferring EP300 vulnerability. Cancer Cell. 2019;36(6):630-644.
5. Kim E, Hurtz C, Koehrer S, et al. Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017;129(9):1155-1165.
6. Polak R, Bierings MB, van der Leije CS, et al. Autophagy inhibition as a potential future targeted therapy for ETV6- RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Haematologica. 2019;104(4):738-748.
7. Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group TARGET Project. Blood. 2013;121(3):485-488.
8. Kohlmann A, Kipps TJ, Rassenti LZ, et al. An international
J. Arceci Innovation Award (to OA).
Data-sharing statement
The data set generated and analyzed during the current study will be made available at PRIDE.1
standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008;142(5):802-807.
9. Geng H, Brennan S, Milne TA, et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012;2(11):1004-1023.
10. Fu T, Zuo Y, Zhong Z, Chen X, Pan Z. Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK). Eur J Med Chem. 2022;229:114051.
11. Geng H, Hurtz C, Lenz KB, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015;27(3):409-425.
12. van der Veer A, van der Velden VH, Willemse ME, et al. Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia. Blood Cancer J. 2014;4(2):e181.
13. Eldfors S, Kuusanmaki H, Kontro M, et al. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia. 2017;31(1):51-57.
14. van de Ven C, Boeree A, Stalpers F, Zwaan CM, Den Boer ML. Ibrutinib is not an effective drug in primografts of TCF3-PBX1. Transl Oncol. 2020;13(10):100817.
15. Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat Rev Drug Discov. 2022;21(9):637-654.
Haematologica | 109 July 2024
2296